AR420626

CAS No. 1798310-55-0

AR420626( AR-420626 | AR 420626 | AR420626 )

Catalog No. M27851 CAS No. 1798310-55-0

AR420626 is a selective fatty acid 3 receptor (FA3R) agonist and provides protective effects against salsolionl (SALS), which was totally blocked by beta-hydroxy butyrate (BHB), a selective FA3R antagonist.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
1 mL x 10 mM in DMSO 75 In Stock
5MG 68 In Stock
10MG 116 In Stock
25MG 258 In Stock
50MG 407 In Stock
100MG 604 In Stock
200MG Get Quote In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    AR420626
  • Note
    Research use only, not for human use.
  • Brief Description
    AR420626 is a selective fatty acid 3 receptor (FA3R) agonist and provides protective effects against salsolionl (SALS), which was totally blocked by beta-hydroxy butyrate (BHB), a selective FA3R antagonist.
  • Description
    AR420626 is a selective fatty acid 3 receptor (FA3R) agonist and provides protective effects against salsolionl (SALS), which was totally blocked by beta-hydroxy butyrate (BHB), a selective FA3R antagonist.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    AR-420626 | AR 420626 | AR420626
  • Pathway
    Others
  • Target
    Other Targets
  • Recptor
    PKMYT1
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    1798310-55-0
  • Formula Weight
    417.29
  • Molecular Formula
    C21H18Cl2N2O3
  • Purity
    >98% (HPLC)
  • Solubility
    In Vitro:?DMSO : 20 mg/mL (47.93 mM)
  • SMILES
    CC1=C(C(c2ccco2)C2=C(CCCC2=O)N1)C(=O)Nc1cc(Cl)ccc1Cl
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1.Charlott Platzer,et al. Identification of PKMYT1 inhibitors by screening the GSK published protein kinase inhibitor set I and II. Bioorg Med Chem. 2018 Aug 7;26(14):4014-4024.
molnova catalog
related products
  • Cerdulatinib

    Cerdulatinib is an novel oral dual Syk/JAK inhibitor.

  • AZD9898

    AZD9898 is an orally active leukotriene-C4 synthetase (LTC4S, glutathione S-transferase II) inhibitor, with an IC50 of 0.28 nM. AZD9898 has the potential to treat asthma. AZD9898 mitigates the GABA binding and hepatic toxicity signal.

  • Forsythoside A

    Forsythoside A has anticomplementary, antimicrobial, antiinflammatory and antiendotoxin activities.